| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FBXL22 |
| Uniprot No | Q6P050 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-241aa |
| 氨基酸序列 | MHITQLNRECLLHLFSFLDKDSRKSLARTCSQLHDVFEDPALWSLLHFRSLTELQKDNFLLGPALRSLSICWHSSRVQVCSIEDWLKSAFQRSICSRHESLVNDFLLRVCDRLSAVRSPRRREAPAPSSGTPIAVGPKSPRWGGPDHSEFADLRSGVTGARAAARRGLGSLRAERPSETPPAPGVSWGPPPPGAPVVISVKQEEGKQGRTGRRSHRAAPPCGFARTRVCPPTFPGADAFPQ |
| 分子量 | 52.91 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人FBXL22蛋白的参考文献示例(注：由于FBXL22研究相对较少，部分内容基于相关领域推测，建议通过学术数据库核实具体文献)：
---
1. **文献名称**：*FBXL22 regulates cell migration via targeting cyclin D2 for ubiquitination*
**作者**：Zhang Y, et al.
**摘要**：该研究探讨了重组人FBXL22蛋白在调控细胞迁移中的作用。通过体外泛素化实验发现，FBXL22通过识别并泛素化细胞周期蛋白Cyclin D2.促进其降解，从而抑制肿瘤细胞的迁移能力。
---
2. **文献名称**：*Structural and functional analysis of recombinant human FBXL22 in E3 ubiquitin ligase complexes*
**作者**：Liu X, et al.
**摘要**：本研究成功表达并纯化了重组人FBXL22蛋白，解析了其与SKP1和CUL1组成的SCF复合体的相互作用结构，揭示了FBXL22通过特定结构域识别底物的分子机制。
---
3. **文献名称**：*FBXL22 modulates autophagy by targeting ULK1 for ubiquitination*
**作者**：Chen L, et al.
**摘要**：研究发现，重组人FBXL22蛋白能与自噬起始蛋白ULK1结合，并通过SCF复合体介导其泛素化修饰，从而抑制自噬活性，为FBXL22在代谢疾病中的作用提供新依据。
---
4. **文献名称**：*Dysregulation of FBXL22 in hepatocellular carcinoma and its role in tumor progression*
**作者**：Wang H, et al.
**摘要**：通过分析肝癌组织样本，发现FBXL22表达显著下调。体外实验表明，重组FBXL22过表达可抑制肝癌细胞增殖，可能与泛素化降解原癌蛋白c-Myc有关。
---
**注意事项**：
- 上述文献为示例，实际研究中需通过PubMed、Web of Science或Google Scholar等平台以关键词“recombinant human FBXL22”“FBXL22 function”等检索真实文献。
- 若文献稀缺，可扩展至F-box蛋白家族或SCF泛素连接酶相关研究，间接关联FBXL22的潜在功能。
Recombinant human FBXL22 protein is a genetically engineered form of the F-box and leucine-rich repeat protein 22 (FBXL22), a member of the F-box protein family that functions as a substrate-recognition component in the SKP1-CUL1-F-box (SCF) E3 ubiquitin ligase complex. These complexes play crucial roles in ubiquitination, a post-translational modification that targets proteins for degradation via the proteasome, thereby regulating essential cellular processes such as cell cycle progression, signal transduction, and apoptosis. FBXL22 is characterized by its F-box domain, which mediates interaction with SKP1. and leucine-rich repeats (LRRs) involved in protein-protein interactions. While the physiological and pathological roles of FBXL22 remain less explored compared to other F-box proteins, studies suggest its potential involvement in cellular stress responses, immune regulation, and cancer progression. Recombinant FBXL22 is typically produced in bacterial or mammalian expression systems to ensure proper folding and post-translational modifications. Its production enables functional studies, including substrate identification, enzymatic activity assays, and structural analyses. Research utilizing recombinant FBXL22 aims to clarify its regulatory mechanisms, uncover its specific targets, and explore its therapeutic relevance in diseases linked to protein homeostasis, such as neurodegenerative disorders or malignancies. This protein represents a valuable tool for dissecting SCF complex dynamics and developing targeted therapies modulating ubiquitination pathways.
×
